Kanefron N in the treatment of non-diabetic glucosuria in patients with recurrent upper urinary tract infection
DOI: https://dx.doi.org/10.18565/urology.2021.3.28-32
B.A. Berdichevsky, V.B. Berdichevsky, V.A. Shidin, A.A. Cologne, А.А. Naletov, S.V. Khilkevich, V.G. Novoselov
1) Tyumen State Medical University of the Ministry of Health of Russia, Tyumen, Russia;
2) «Regional Clinical Hospital No. 2», Tyumen, Russia;
3) Medical hospital "Oilman", Tyumen, Russia
Aim. Purpose to analyze the effectiveness of the herbal preparation Canephron N in the relief of nondiabetic glucosuria in patients with recurrent upper urinary tract infection (UTI).
Materials and methods: the study included 100 patients, 53 of them were women (median age of all patients 42 (35; 58) years) with recurrent UTI. Patients were referred to the urology department to exclude the obstructive component and concomitant chronic diseases. Upon further examination, all patients were found to have nondiabetic glucosuria. Fifty patients received standard etiotropic treatment, in 25 patients it was simultaneously supplemented with the herbal drug Canephron N, and 25 patients, after standard treatment, continued monotherapy with this phytopreparation. Clinical and laboratory dynamics was assessed in the course of various treatment regimens.
Results. The study found that the recurrent course of chronic UTI may be associated with nondiabetic glucosuria. In patients who received standard therapy in combination with the herbal preparation Kanephron N, a decrease in the intensity of nondiabetic glucosuria with more effective eradication of the bacterial pathogen was noted. At the same time, monotherapy of manifestations of IVMP, which are refractory to etiotropic therapy, with Kanefron N also proved to be quite effective.
Conclusion: the combination of standard therapy for refractory manifestations of UTI with the herbal preparation Kanephron N is accompanied by the leveling of nondiabetic glucosuria (1.3±0.4 and 0.6±0.4 mmol/L, p<0.05), coinciding with a decrease in leukocyturia (25.5±4.5 and 9.5±1.5 in field of vision, p<0.05)
About the Autors
Corresponding author: B.A. Berdichevsky – Ph.D., MD, professor, professor at the Department of Oncology with a course of Urology of FGBOU VO Tyumen State Medical University of the Ministry of Health of Russia, Tyumen, Russia; e-mail: doktor_bba@mail.ru
Similar Articles